# RNN 2nd Gen Model Amgen Inc. Biological products, except diagnostic

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
82.56%Expected margin
100.00% successful of 6 deals
$ 227.04 Last close price
at 01-mar-2021


Model's trade recommendations No return for period yet

1.91% Annual return

$112.11B Market Cap

β 1.36  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return
52wk Range
Sortino ratio 76.27
Sharpe ratio 0.82
Norm. RMSE 82.62%
Downside risk 0.02%
Volatility 0.00%
  • 5.28 (3.12%) Div (Yield)
  • BUY Analysts consensus recommendation

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Amgen Inc. (AMGN) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for AMGN model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for AMGN.

Model is being retrained on a regular basis.

Float 660M
P/E 13.13
Shares Outstanding 662M
% Held by Insiders 0.19%
% Held by Institutions 85.73%
EPS (last reported FY) $12.58
EPS (last reported Q) $3.47
EPS, estimated (last reported Q) $3.23
Total revenues $23 B
Net income $2 B